Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor von Zhao, Yujie, Adjei, Alex A.

Volltext

Blocking Oncogenic Ras Signaling for Cancer Therapy von ADJEI, Alex A

Volltext

Current Diagnosis and Management of Small-Cell Lung Cancer von Wang, Shuhang, Zimmermann, Stefan, Parikh, Kaushal, Mansfield, Aaron S., Adjei, Alex A.

Volltext

Novel Agents on the Horizon for Cancer Therapy von Ma, Wen W, Adjei, Alex A

Volltext

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches von Uprety, Dipesh, Mandrekar, Sumithra J., Wigle, Dennis, Roden, Anja C., Adjei, Alex A.

Volltext

Targeting Apoptosis Pathways in Cancer Therapy von Ghobrial, Irene M, Witzig, Thomas E, Adjei, Alex A

Volltext

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Peters, S, Adjei, A A, Gridelli, C, Reck, M, Kerr, K, Felip, E

Volltext

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions von Peters, Solange, Zimmermann, Stefan, Adjei, Alex A

Volltext

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy von FRIDAY, Bret B, ADJEI, Alex A

Volltext

Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis von Reungwetwattana, Thanyanan, Adjei, Alex A.

Volltext

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer von Nguyen-Ngoc, Tu, Bouchaab, Hasna, Adjei, Alex A., Peters, Solange

Volltext

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer von GOETZ, Matthew P, TOFT, David, SALAZAAR, Sandra, ADJEI, Alex, CROGHAN, Gary, ERLICHMAN, Charles, REID, Joel, AMES, Matthew, STENSGARD, Bridget, SAFGREN, Stephanie, ADJEI, Araba A, SLOAN, Jeff, ATHERTON, Pamela, VASILE, Vlad

Volltext

Human aromatase : Gene resequencing and functional genomics von MA, Cynthia X, ADJEI, Araba A, WEINSHILBOUM, Richard M, SALAVAGGIONE, Oreste E, CORONEL, Josefa, PELLEYMOUNTER, Linda, LIEWEI WANG, ECKLOFF, Bruce W, SCHAID, Daniel, WIEBEN, Eric D, ADJEI, Alex A

Volltext

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations von Remon, Jordi, Passiglia, Francesco, Ahn, Myung-Ju, Barlesi, Fabrice, Forde, Patrick M., Garon, Edward B., Gettinger, Scott, Goldberg, Sarah B., Herbst, Roy S., Horn, Leora, Kubota, Kaoru, Lu, Shun, Mezquita, Laura, Paz-Ares, Luis, Popat, Sanjay, Schalper, Kurt A., Skoulidis, Ferdinandos, Reck, Martin, Adjei, Alex A., Scagliotti, Giorgio V.

Volltext

ALK inhibitors in the treatment of advanced NSCLC von Gridelli, Cesare, Peters, Solange, Sgambato, Assunta, Casaluce, Francesca, Adjei, Alex A, Ciardiello, Fortunato

Volltext

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship von Molina, Julian R., MD, PhD, Yang, Ping, MD, PhD, Cassivi, Stephen D., MD, Schild, Steven E., MD, Adjei, Alex A., MD, PhD

Volltext

KRAS: From undruggable to a druggable Cancer Target von Uprety, Dipesh, Adjei, Alex A.

Volltext

Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426 von ADJEI, Alex A, MANDREKAR, Sumithra J, ZINNER, Ralph G, DY, Grace K, MOLINA, Julian R, ADJEI, Araba A, GANDARA, David R, ALLEN ZIEGLER, Katie L, STELLA, Philip J, ROWLAND, Kendrith M, SCHILD, Steven E

Volltext

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational coho... von Luo, Yung-Hung, MD, Luo, Lei, PhD, Wampfler, Jason A, BS, Wang, Yi, MD, Liu, Dan, MD, Chen, Yuh-Min, Prof, Adjei, Alex A, Prof, Midthun, David E, Prof, Yang, Ping, Prof

Volltext

Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy von ADJEI, Alex A, HIDALGO, Manuel

Volltext